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Overall the D2cc values for the OAR have a lower percentage 
difference between planners than the D0.1cc due to the increased 
influence within the small volume. 
Conclusions: T2 MR imaging alone for reconstruction, using the 
external applicator surface, is reproducible between different 
planners. Slice thickness and inter-space gap are known parameters 
that can lead to uncertainties in applicator reconstruction, but by 
using mutual information from orthogonal sequences these 
uncertainties can be minimised. 
The changes in DVH parameters between planners are small, for both 
HR-CTV and all OARs, and would not result in a clinically significant 
change in terms of optimisation approach for the treatment plan. 
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Purpose/Objective: For brachytherapy of cervical cancers, the 
imaging modality of choice for delineation of targets and organ at 
risks (OAR) is T2-weighted MR imaging. Applicator reconstruction using 
MR imaging can be problematic for applicators composed of titanium. 
Titanium generates susceptibility artefacts on MR scans, causing signal 
voids near the titanium that may hamper applicator reconstruction. 
The goal of this study is to propose a novel MR sequence that yields 
non-deformed, high resolution and high contrast images that can be 
used for accurate and reproducible reconstruction of titanium 
applicators. The method is tested using a new design of the tandem 
and ovoid titanium Rotterdam applicator (Nucletron). 
Materials and Methods: A 1.5 Tesla MR scanner was used with a 3D 
radiofrequency Spoiled Gradient Recalled Echo sequence (SPGR, TE: 
1.1 ms, TR: 2.5, voxel size: 1.4x1.4x1.6 mm3, flip angle: 3o, number of 
excitations: 3) for imaging and applicator reconstruction. The 
geometrical accuracy of the applicator in the images was assessed 
using an in house developed gel filled phantom that could fixate the 
applicator. The inter-observer variability of applicator reconstruction 
was studied by analysing the results of eight different technicians that 
each performed applicator reconstruction for four different patients. 
The rigidity of the applicator allowed the use of a single library 
applicator, a digital model of the applicator with fixed dimensions, for 
applicator reconstruction. 
Results: On a standard T2 weighted scan, the titanium did not 
produce artefacts that hampered tumour delineation, but the contrast 
between the applicator and uterus was not sufficient for accurate 
applicator reconstructions. The 3D SPGR scan sequence yielded an 
excellent contrast between the soft tissues and the applicator, which 
was clearly visible as a signal void. When the intra-uterine was aligned 
with the B0 field,the width (FWHM) of its signal void was exactly 
equal to the real diameter of 3.0 mm, but it increased to 6.2 mm 
when the intra-uterine was tilted 46ocompared to the B0 field. 
Because the intra-uterine tube was located in the centre of the signal 
void (within 0.7 mm), the accuracy of applicator reconstruction was 
not affected by the expansion of the signal void for large tilt 
angles.This was confirmed by the excellent inter-observer variability 
among the eight technicians. The mean deviation for all reconstructed 
dwell positions was smaller than 1.0 mm and the maximum deviation 
of any dwell position among all patients and technicians was only 1.7 
mm. 
Conclusions: The titanium applicator was clearly visible on the 3D 
SPGR MR images, allowing applicator reconstruction with excellent 
accuracy and reproducibility. When used in addition to the standard 
T2 weighted MR images for tumour and OAR delineation, high 
accuracy MR guided brachytherapy is feasible with a titanium 
applicator. 
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Purpose/Objective: To compare the uncertainties of CT and MRI-T1 
based seed reconstruction in post-implant evaluation of permanent 
prostate brachytherapy in terms of interobserver variability, and to 
quantify the impact of this seed detection variability on a selection of 
dosimetric parameters for three postplan techniques: 1) CT only, 2) 
MRI-T1 fused with MRI-T2, and 3) CT fused with MRI-T2. 
Materials and Methods: Seven physicists reconstructed the seed 
positions on post-implant CT and MRI-T1 weighted images of three 
patients treated with I-125 seed brachytherapy. A reference seed set 
was defined by two experienced physicists. The reconstructed seeds 
were assigned to the reference seeds within an acceptance diameter 
of 15mm, using a dedicated Matlab program. For each patient and 
imaging modality the interobserver variability was calculated with 
respect to the reference (1 SDref). The effect of this variability on 
dosimetry (D90, V100, V150) was calculated for CT and for CT + MRI-T2 
(both techniques using CT based seed reconstruction), as well as for 
MRI-T1 + MRI-T2 (using MRI-T1 based seed reconstruction), for a fixed 
CT and MRI-T2 prostate contour. Contouring was done by two 
experienced uro-radiologists based on the post-implant CTV-P(rostate) 
definition according to the ESTRO/EAU/EORTC prostate recom-
mendations. 
Results: For CT, on average 98 % of the reconstructed seeds could be 
assigned to a reference seed, while the mean seed assignment rate for 
T1 was 93 %. Averaged over three patients, the interobserver 
variability in CT based seed reconstruction was 1.1 mm (1 SDref). This 
resulted in D90 variabilities < 2% (1 SDref) for CT and CT + MRI-T2, 
which is clinically acceptable (see table). Also the interobserver 
variabilities in V100 and V150 were small, with patient mean SDref values 
< 1% and < 4% respectively.  
The mean interobserver variability in MRI based seed reconstruction 
was 3.0 mm (1 SDref). This would be even larger if non-assigned seeds 
(outside the acceptance diameter) would be taken into account. The 
larger seed detection uncertainties on MRI-T1 compared to CT are due 
to the lack of an automated seed finder tool, and the fact that seeds 
are less clearly depicted on MRI. The impact of the interobserver 
variability on D90 was 6.6% for MRI-T1 + MRI-T2. 
Conclusions: Seed reconstruction on MRI-T1-weighted images was less 
accurate than on CT. This difference in uncertainties should be taken 
into account and weighted against uncertainties due to contouring and 
image fusion when comparing the overall reliability of postplan 
techniques. 
Table: Interobserver variability in seed reconstruction (averaged over 
three patients), expressed as (a) positional deviation (mm) and (b) 
dosimetric impact (%) with respect to the reference values. 
 
SDref in seed reconstruction (mm) CT MR-T1 
 1.1 mm 3.0 mm SDref in dosimetry (%) CT CT + MR-T2MR-T1 + MR-T2 
D90 
V100 
V150 
1.5 
0.9 
3.6 
1.3 
0.5 
3.2 
6.6 
2.8 
8.1 
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Purpose/Objective: The current clinical low dose rate (LDR) 
brachytherapy dosimetry protocol for low energy photons, AAPM 
TG43, ignores the effects of tissue composition. Given the 
photoelectric effect's dominance at the low photon energies, the 
dosimetry is dependent on the elemental composition and density of 
tissues. AAPM TG186 recently recommended that brachytherapy dose 
calculations take heterogeneities into account by using CT images. In 
LDR seed implants, metal streaking artefacts degrade density (ρ) 
information and limit the applicability of heterogeneity corrections. 
Metal artefact reduction (MAR) techniques have been presented, but 
are currently not clinically implemented in radiotherapy, possibly due 
to their complexity. Dual energy CT (DECT) imaging allows the 
reconstruction of mono energetic attenuation maps over a range of 
diagnostic energies. It has recently been shown that by carefully 
